European Registry of Severe Cutaneous Adverse Reactions (SCAR) to Drugs and Collection of Biological Samples (RegiSCAR)

The aim of the RegiSCAR-study group is to reduce the medical and economic burden of severe cutaneous adverse reactions (SCAR) on public health and to improve the safety of medication use. The practical objectives are: 1) to build an European Registry of SCAR for continuous surveillance of new drugs with adequate pharmacoepidemiologic methodology and for providing reference information on SCAR,2) to organize a centralized collection of biological samples to allow high quality studies on pharmacogenetics and investigations of the mechanisms of these reactions,3) to follow a cohort of SCAR-patients to study the outcome,prognosis,sequelae and impact on quality of life of these severe side effects of medicine.The Registry collects well ascertained cases and minimize bias on drug causality (validation done blindly from drug exposure). Pharmacovigilance based on spontaneous reports raises alerts,RegiSCAR is able to confirm and quantify the risks.